D L Carlson Investment Group Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 31.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,558 shares of the company's stock after purchasing an additional 1,575 shares during the period. Eli Lilly and Company makes up approximately 1.3% of D L Carlson Investment Group Inc.'s holdings, making the stock its 15th largest position. D L Carlson Investment Group Inc.'s holdings in Eli Lilly and Company were worth $7,866,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Portfolio Design Labs LLC lifted its stake in shares of Eli Lilly and Company by 10.1% in the 2nd quarter. Portfolio Design Labs LLC now owns 9,672 shares of the company's stock worth $11,601,000 after purchasing an additional 889 shares during the period. Fischer Financial Services Inc. raised its position in Eli Lilly and Company by 9.4% in the second quarter. Fischer Financial Services Inc. now owns 2,353 shares of the company's stock worth $2,823,000 after acquiring an additional 202 shares during the period. Ninepoint Partners LP purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth $3,370,000. SGL Investment Advisors Inc. grew its position in shares of Eli Lilly and Company by 15.7% during the 2nd quarter. SGL Investment Advisors Inc. now owns 923 shares of the company's stock valued at $1,137,000 after acquiring an additional 125 shares during the period. Finally, Advisors Capital Management LLC increased its stake in shares of Eli Lilly and Company by 305.0% in the 2nd quarter. Advisors Capital Management LLC now owns 38,507 shares of the company's stock worth $46,187,000 after purchasing an additional 29,000 shares in the last quarter. 82.53% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on LLY shares. Morgan Stanley reiterated an "overweight" rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Sanford C. Bernstein lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research report on Tuesday, July 14th. Bank of America boosted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $1,400.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.
Get Our Latest Analysis on Eli Lilly and Company
Insiders Place Their Bets
In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last 90 days. 0.14% of the stock is currently owned by corporate insiders.
More Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: The FDA approved a blood test developed by Lilly and Roche to help identify Alzheimer’s disease. The simpler diagnostic could expand access to testing and support demand for Lilly’s Alzheimer’s drug Kisunla. Eli Lilly Clears Big Hurdle in Alzheimer's Fight
- Positive Sentiment: A real-world study found that adults over 55 who continued using Zepbound had fewer hospital admissions and emergency-room visits, reducing healthcare costs relative to similar untreated patients. The findings could strengthen the case for Medicare and other payer coverage of the obesity drug. Zepbound linked to lower healthcare costs
- Positive Sentiment: Lilly is expanding its Alzheimer’s pipeline with new early-stage Phase 1 studies, providing additional potential beyond Kisunla. Lilly Expands Alzheimer’s Pipeline
- Neutral Sentiment: Recent institutional activity was mixed, with major investors both adding to and reducing LLY positions. Analysts’ median price target of approximately $1,348 remains above the recent trading level, but valuation and elevated expectations may limit near-term upside.
- Negative Sentiment: Renewed concern over reimbursement is weighing on sentiment. Some employers are becoming more selective about covering GLP-1 weight-loss drugs, raising questions about future Zepbound and oral obesity-drug volume growth. Companies Decline to Cover Weight-Loss Drug Costs
- Negative Sentiment: The cost-savings study may be less persuasive to payers because it measures medical savings without clearly including Zepbound’s price, leaving uncertainty about whether treatment produces net savings. Lilly's Cost-Saving Study Leaves Out Zepbound's Price
- Negative Sentiment: After a strong rally and a recent record high, profit-taking appears to be amplifying the reimbursement concerns. Healthcare stocks also declined late in the session. Eli Lilly Stock Pulls Back After Hitting Record Highs
Eli Lilly and Company Stock Down 3.4%
NYSE LLY opened at $1,191.49 on Thursday. Eli Lilly and Company has a 12 month low of $712.05 and a 12 month high of $1,292.65. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.12 trillion, a PE ratio of 39.98, a P/E/G ratio of 1.46 and a beta of 0.51. The stock's 50 day moving average is $1,186.29 and its 200 day moving average is $1,063.74.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. During the same quarter last year, the business posted $6.31 earnings per share. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts predict that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's payout ratio is presently 23.22%.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
